Having uncovered genomic activation of PPARγ/RXRα pathway as a potential resistance mechanism to immunosurveillance and immunotherapies, we next attempted to explore the impact of therapeutic targeting of RXRα or PPARγ on inflammatory gene expression as an initial step to restore the inflamed immuno-environment and immune-response in bladder cancer. This evidence concerns the gene RXRA and urinary bladder cancer.